| Name | Title | Contact Details |
|---|
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Our products are helping to address some of today’s biggest challenges, including global population growth, an aging society and the need to make efficient – and, wherever possible, sustainable – use of natural resources. We are improving people’s quality of life by preventing, alleviating or curing diseases. We are helping to provide an adequate supply of high-quality food, feed and renewable plant-based raw materials. In line with our mission “Bayer: Science For A Better Life”, we aim to improve people’s quality of life. For this endeavor, we focus on our core competency of developing and successfully commercializing innovative products and solutions based on scientific knowledge.
Elligo Health Research helps speed new therapies to market by providing large numbers of patients and clinicians the opportunity to participate in clinical research. Elligo enables rapid and effective clinical trial enrollment and facilitates the study site operations so that clinicians can focus on their research. Our unique direct to patient model allows us to streamline patient identification and qualification, site activation, patient enrollment, study initiation and study conclusion for more efficient and cost-effective trials.
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates that are designed to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA. As a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. These premature stop codons have been identified in over 1,800 rare and ultra-rare diseases. Read-through therapeutic development is focused on extending mRNA half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. Eloxx`s lead product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. ELX-02 is in the early stages of clinical development focusing on cystic fibrosis and cystinosis. ELX-02 is an investigational drug that has not been approved by any global regulatory body. Eloxx is headquartered in Waltham, MA, with R&D operations in Rehovot, Israel.
We`re a company that takes on the toughest health challenges. But we do more than treat diseases—we aim to make a remarkable impact on people`s lives. We are AbbVie, a highly focused research-driven biopharmaceutical company. Our ~30,000 employees are scientists, researchers, communicators, manufacturing specialists and regulatory experts located around the globe. We come up with new approaches to addressing today`s health issues—from life-threatening illness to chronic conditions. We target specific difficult-to-cure diseases where we can leverage our core R&D expertise to advance science. We`re constantly working to create solutions that go beyond treating the illness to have a positive impact on patients` lives, on societies—and on science itself. At AbbVie, we see a future full of possibility, where health is in reach and patient lives are improved. See our employees, our science and our hope for tomorrow: Our purpose is profound, and our path is clear. We embrace the responsibility of making a remarkable impact on people`s lives through the innovative medicines and solutions we create together. This is driven by our compassion for people, commitment to innovation and inclusion, service to the community, and uncompromising integrity at the heart of everything we do. Operating as one AbbVie team, we care deeply for our patients, their families, our employees, and our communities. We strive to always do the right thing, pursuing the highest standards in quality, compliance, safety, and performance. In everything we do, we invest and innovate relentlessly to tackle unmet needs, creating new medicines and healthcare approaches for a healthier world. Globally, our employees embrace diverse backgrounds and perspectives and treat everyone equally, with dignity and respect, allowing us all to achieve our best. We proudly do our part to serve and support our communities and protect the environment, making a lasting impact that`s felt within healthcare and beyond. What we do isn`t easy, but we persevere because what we achieve inspires hope and transforms lives—every single day.
Vancouver Clinic has medical clinics, urgent care facilities, highly rated doctors and laboratories. Located in Southwest Washington.